StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

Investment analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, HC Wainwright initiated coverage on vTv Therapeutics in a research report on Wednesday, April 9th. They set a “buy” rating and a $36.00 target price on the stock.

vTv Therapeutics Stock Up 4.7 %

Shares of NASDAQ:VTVT opened at $19.70 on Wednesday. The company has a market capitalization of $62.84 million, a price-to-earnings ratio of -4.35 and a beta of 0.81. The company has a 50 day moving average of $18.06 and a two-hundred day moving average of $15.90. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $29.19.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. JPMorgan Chase & Co. purchased a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 1,803 shares of the biotechnology company’s stock, valued at approximately $25,000. JPMorgan Chase & Co. owned about 0.06% of vTv Therapeutics at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.